Tesamorelin
A growth hormone–releasing hormone analog FDA-approved (Egrifta) for a specific medical indication.
What it is
Tesamorelin is a stabilized GHRH analog and a genuine FDA-approved drug: as Egrifta, it is indicated for reducing excess visceral abdominal fat in HIV-associated lipodystrophy.
Its trials showed meaningful visceral-fat reduction in that specific population — which makes it the favorite citation of GH-axis marketing aimed at everyone else. The approval and its evidence belong to a defined patient group; general-population fat-loss use is off-label extrapolation with cost and monitoring implications a prescriber should own.
What researchers have actually studied it for
Visceral fat reduction in HIV-associated lipodystrophy — its approved indication, backed by controlled trials in that population.
How it works
Tesamorelin is growth-hormone-releasing hormone with a stabilizing modification that resists enzymatic breakdown. It drives the pituitary's own pulsatile GH release, raising IGF-1 — and its measured downstream effect in trials was selective reduction of visceral (deep abdominal) fat.
Where it came from
Developed by Theratechnologies for the fat-redistribution syndrome affecting people on long-term HIV therapy, tesamorelin won FDA approval in 2010 — making it the only GHRH analog with a current US drug approval, and the scientific anchor for every 'GHRH peptide' conversation since.
What the research record actually contains
- Two placebo-controlled phase 3 trials in HIV-associated lipodystrophy: ~15–18% average visceral-fat reduction over 26 weeks.
- IGF-1 elevation and GH-axis engagement consistently demonstrated.
- Investigator studies in NAFLD and cognition exist but haven't changed the approved indication.
- No approval or major trials for general-population fat loss.
What's known about risks
Label-documented: injection-site reactions, joint aches, fluid retention, and — the clinically important one — worsened glucose control in some patients, requiring monitoring. Effects reverse when stopped; visceral fat also returns, per trial extensions.
Where it stands legally
Prescription-only, approved for a specific indication; off-label prescribing is lawful physician territory but leaves the evidence behind. Compounded 'tesamorelin' in wellness programs occupies the usual eligibility gray zone a licensed pharmacy must answer for.
Worth asking a licensed provider
- 1.Am I in — or near — the population its trials actually studied?
- 2.If off-label, what monitoring (especially glucose) will we run?
- 3.What happens to results when treatment stops, and what's the exit plan?